CHAIN Appoints New Non-Executive Directors
MARLOW & NOTTINGHAM, UK. — April 8, 2019 – UK microbiome therapeutics company CHAIN Biotechnology…read more
CHAIN Biotechnology Ltd was founded by Dr Edward Green in 2014 to develop new Clostridium-based microbial technology for high value healthcare products. CHAIN produces novel live biotherapeutic products (LBPs) for chronic gut-related diseases, such as Inflammatory Bowel Disease (IBD).
At the heart of CHAIN’s unique therapeutic platform is a suite of underpinning technologies including a Clostridia culture collection, a proprietary set of plasmid vectors, synthetic biology tools for advanced metabolic engineering, and an advanced in-vivo delivery mechanism using Clostridium.
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
”An expansive view of design has been adopted at CHAIN Biotechnology, which is developing...read more
CHAIN has worked closely with the University of Nottingham since our beginning, and it...read more